Current Edition

clinical

Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer

SOTIO, a biotechnology company owned by the PPF Group, presented results from its Phase II clinical trials evaluating DCVAC, an active cellular immunotherapy product, in …

Continue Reading →
DCVAC

SOTIO Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy

SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination …

Continue Reading →